Completed PHASE3 NCT00188630

N-Acetylcysteine for Preventing Renal Injury After Cardiac Surgery

The PRIME (Perioperative Renal Insufficiency Management) Study: A Randomized, Double-blinded, Placebo-controlled Trial of N-acetylcysteine for Preventing Renal Injury After Cardiac Surgery.

Sponsor: Heart and Stroke Foundation of Ontario

Conditions Acute Renal Failure Heart Disease

Interventions 5% dextrose solution N-acetylcysteine

Updated 5 times since 2017 Last updated: Apr 19, 2011 Started: Jul 31, 2003 Primary completion: Feb 28, 2007 Completion: Jul 31, 2007

Listed as NCT00188630, this PHASE3 trial focuses on Acute Renal Failure and Heart Disease and remains completed. Sponsored by Heart and Stroke Foundation of Ontario, it has been updated 5 times since 2003, reflecting limited change activity. This study contributes longitudinal data to the cardiovascular research landscape.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3
Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Jul 2003

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Heart and Stroke Foundation of Ontario
University Health Network, Toronto

Data source: University Health Network, Toronto

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Toronto, Canada